PMID- 36733388
OWN - NLM
STAT- MEDLINE
DCOM- 20230206
LR  - 20230217
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Exosomes as smart drug delivery vehicles for cancer immunotherapy.
PG  - 1093607
LID - 10.3389/fimmu.2022.1093607 [doi]
LID - 1093607
AB  - Exosomes (Exos) as drug delivery vehicles have been widely used for cancer 
      immunotherapy owing to their good biocompatibility, low toxicity, and low 
      immunogenicity. Some Exos-based cancer immunotherapy strategies such as tuning of 
      immunosuppressive tumor microenvironment, immune checkpoint blockades, and cancer 
      vaccines have also been investigated in recent years, which all showed excellent 
      therapeutic effects for malignant tumor. Furthermore, some Exos-based drug 
      delivery systems (DDSs) for cancer immunotherapy have also undergone clinic 
      trails, indicating that Exos are a promising drug delivery carrier. In this 
      review, in order to promote the development of Exos-based DDSs in cancer 
      immunotherapy, the biogenesis and composition of Exos, and Exos as drug delivery 
      vehicles for cancer immunotherapy are summarized. Meanwhile, their clinical 
      translation and challenges are also discussed. We hope this review will provide a 
      good guidance for Exos as drug delivery vehicles for cancer immunotherapy.
CI  - Copyright (c) 2023 Zhang, Wang, Sun, Cui, Xing, Teng, Xi and Yang.
FAU - Zhang, Huan
AU  - Zhang H
AD  - School of Life Sciences, Jilin University, Changchun, China.
FAU - Wang, Simiao
AU  - Wang S
AD  - School of Life Sciences, Jilin University, Changchun, China.
FAU - Sun, Man
AU  - Sun M
AD  - School of Life Sciences, Jilin University, Changchun, China.
FAU - Cui, Yaxin
AU  - Cui Y
AD  - School of Life Sciences, Jilin University, Changchun, China.
FAU - Xing, Jianming
AU  - Xing J
AD  - School of Life Sciences, Jilin University, Changchun, China.
FAU - Teng, Lesheng
AU  - Teng L
AD  - School of Life Sciences, Jilin University, Changchun, China.
FAU - Xi, Zhifang
AU  - Xi Z
AD  - School of Horticulture and Food, Guangdong Eco-Engineering Polytechnic, 
      Guangzhou, China.
FAU - Yang, Zhaogang
AU  - Yang Z
AD  - School of Life Sciences, Jilin University, Changchun, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230117
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Drug Carriers)
SB  - IM
MH  - *Exosomes
MH  - Cell Line, Tumor
MH  - Drug Delivery Systems
MH  - Drug Carriers
MH  - Immunotherapy
MH  - *Neoplasms/therapy
PMC - PMC9888251
OTO - NOTNLM
OT  - drug delivery system
OT  - exosomes
OT  - immune checkpoint blockade
OT  - immunotherapy
OT  - tumor immune microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/02/04 06:00
MHDA- 2023/02/07 06:00
PMCR- 2022/01/01
CRDT- 2023/02/03 01:55
PHST- 2022/11/10 00:00 [received]
PHST- 2022/12/23 00:00 [accepted]
PHST- 2023/02/03 01:55 [entrez]
PHST- 2023/02/04 06:00 [pubmed]
PHST- 2023/02/07 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1093607 [doi]
PST - epublish
SO  - Front Immunol. 2023 Jan 17;13:1093607. doi: 10.3389/fimmu.2022.1093607. 
      eCollection 2022.